Paul Schimmel's Net Worth
$248 Million
Who is Paul Schimmel?
Paul Schimmel has an estimated net worth of $248 Million. This is based on reported shares across multiple companies, which include ALNYLAM PHARMACEUTICALS, INC., Sirtris Pharmaceuticals, Inc., Avicena Group, Inc., REPLIGEN CORP, Tocagen Inc, aTYR PHARMA INC, and ALKERMES INC.
SEC CIK
Paul Schimmel's CIK is 0001236447
Past Insider Trading and Trends
2016 was Paul Schimmel's most active year for acquiring shares with 22 total transactions. Paul Schimmel's most active month to acquire stocks was the month of March. 2007 was Paul Schimmel's most active year for disposing of shares, totalling 41 transactions. Paul Schimmel's most active month to dispose stocks was the month of October. 2021 saw Paul Schimmel paying a total of $2,199,000.00 for 551,428 shares, this is the most they've acquired in one year. In 2018 Paul Schimmel cashed out on 55,646 shares for a total of $4,173,450.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Snapshot price: $169.015
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
|
—
|
0
|
$99.62 | -$2,803,523.22 |
0
|
Scheduled
|
Mar 13
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
| -1.29% | -4.00K |
—
|
—
| 307K |
Nov 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
$79.36 | -$1,013,350.00 |
0
|
Scheduled
|
Apr 21
| ||
Form 4
|
—
|
0
|
$73.64 | -$927,200.00 |
0
|
Scheduled
|
Mar 17 - Mar 19
| ||
Form 4
|
—
|
0
|
$63.55 | -$1,243,650.00 |
0
|
Scheduled
|
Dec 8
| ||
Form 4
|
—
|
0
|
$55.46 | -$1,186,350.00 |
0
|
Scheduled
|
Oct 28
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 5
| |||
Form 4
|
—
|
0
|
$50.59 | -$1,043,100.00 |
0
|
Scheduled
|
Jan 13
| ||
Form 4
| -1.11% | -3.50K |
—
|
—
| 311K |
Dec 26 - Jan 2
| |||
Form 4
|
—
|
0
|
$38.17 | -$805,050.00 |
0
|
Scheduled
|
Dec 20
| ||
Form 4
|
—
|
0
|
$34.65 | -$760,500.00 | 126.22K |
Scheduled
|
Oct 22
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
| +58.47% | 93.02K |
$10.75 | $999,997.25 | 252.11K |
Feb 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
| -22.28% | -45.60K |
$22.15 | -$1,010,219.76 | 159.09K |
Sep 9 - Sep 10
| |||
Form 4
| -12.56% | -29.40K |
$22.02 | -$647,482.08 | 204.69K |
Sep 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
| -3.64% | -11.19K |
$31.89 | -$229,363.80 | 296.47K |
Dec 3 - Dec 4
| |||
Form 4
| -8.56% | -28.81K |
$22.10 | -$1,402,603.90 | 307.67K |
Nov 30 - Dec 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
| +42.00% | 100K |
$13.00 | $1,300,000.00 | 338.09K |
Jan 31
| |||
Form 4
| +0.03% | 74 |
—
|
—
| 238.09K |
Sep 19
| |||
Form 4
| +0.05% | 121 |
—
|
—
| 238.01K |
Sep 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
| +15.31% | 31.58K |
—
|
—
| 237.89K |
Jun 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sirtris Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.70% | 15.28K |
$8.71 | -$184,316.33 | 340.52K |
Nov 30
| |||
Form 4
| +455.29% | 266.67K |
—
|
—
| 325.24K |
May 29
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Avicena Group, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +2.84% | 33.24K |
—
|
—
| 1.21M |
Nov 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
REPLIGEN CORP (RGEN) Snapshot price: $201.93
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +0.76% | 5K |
$1.00 | $5,000.00 | 665.11K |
Jun 14
| |||
Form 4
| -0.45% | -3.00K |
—
|
—
| 660.11K |
Feb 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 15
| |||
Form 4
| +0.76% | 5K |
$0.88 | $4,400.00 | 663.11K |
Aug 11
| |||
Form 4
| -3.03% | -20.58K |
—
|
—
| 658.11K |
Nov 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 10
| |||
| No matching records found | |||||||||
Tocagen Inc (FBRX) Snapshot price: $0.5935
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
∞
| 44.83K |
$10.00 |
—
| 44.83K |
Apr 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||